All lobbying filings

Astellas Pharma US, Inc.

Astellas Pharma US, Inc. filed a Q3 report for Astellas Pharma US, Inc. on October 20, 2025.

Lobbying for Astellas Pharma US, Inc.

As filed: ASTELLAS PHARMA US, INC. for ASTELLAS PHARMA US, INC.

All filings by Astellas Pharma US, Inc. · Everything Astellas Pharma US, Inc. has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Expenses

$850,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Illinois

Official filing document

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 4

Taxation/Internal Revenue Code

Issues related to OBBA (Pub. L. No: 119-21).

Medicare/Medicaid

Issues pertaining to Medicare Part D; H.R. 1300/S. 297 PSA screening bills; Issues related to the Inflation Reduction Act (Pub. L. 117-169); Issues related to OBBA (Pub. L. No: 119-21).

Health Issues

H.R. 1300/S. 297, PSA screening bills; Issues related to Women's Health and Menopause (no specific bills); Issues related to Eye Screening and Access (no specific bills); Issues related to implementation of the Inflation Reduction Act (Pub. L. 117-169); Issues Related to OBBA (Pub. L. No: 119-21); Issues related to health care transparency.

Issues related to IP/Bayh-Dole Act (Pub.L. 96-517).

Bills named in this filing 2

H.R. 1300
PSA Screening for HIM Act
S. 297
PSA Screening for HIM Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.